XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Home
Menu

Sarcoma Trials

A list of our early phase sarcoma trials which are open to recruitment at University College London Hospitals

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Sarcoma cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

 

IMMUNOSARC2

Phase I - II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas

Local Project Reference:17/0246
Principal Investigator:Dr. Sandra Strauss
Drug Class/ Treatment:

Nivolumab (PD-1 inhibiting IgG4 Monoclonal Antibody) and Sunitinib (RTK Inhibitor)

Combination Treatment - Nivolumab IV and Sunitinib Oral Administration

Patient Population:

Advanced Soft Tissue and Bone Sarcomas

Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

 

GSK 208467 NY-ESO (GSK 3377794)

GSK3377794 safety & efficacy in NY-ESO positive solid tumour:  Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Local Project Reference:127000
Principal Investigator:Dr. Sandra Strauss
Drug Class/ Treatment:GSL3377794 (T-Cell Immunotherapy)
Patient Population:

Advanced Synovial Sarcoma or Liposarcoma

HLA-A2+ Participants with NY-ESO and/or LAGE-1a Positive Solid Tumours

Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

FaR-RMS

An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

Local Project Reference:120376
Principal Investigator:Dr. Maria Michelagnoli
Drug Class/ Treatment:

Trial of various Immunotherapy, Targeted Therapy Agents and Radiotherapy.

Patient Population:

Newly Diagnosed and Relapsed Rhabdomyosarcoma (RMS)

Age >12 months and ≤25 years

Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

SPEARHEAD-1

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Local Project Reference:125255
Principal Investigator:Dr. Sandra Strauss
Drug Class/ Treatment:

ADP-A2M4 SPEAR™ T Cells - Genetically Modified T-Cells targeting MAGEA4 (Melanoma-Associated Antigen 4)

Patient Population:

Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Age 16 - 75

Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)